https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Ophthalmology
ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome

ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome

ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye drops for the treatment of dry eye syndrome. The company is a US-based joint venture company between GtreeBNT and RegeneRx Biopharmaceuticals. ARISE-3 is a randomized, double-masked, placebo-controlled trial which will evaluate the 0.1% RGN-259 eye […]

Biogen to acquire UK gene therapy company Nightstar Therapeutics for $800m

Biogen acquisition of Nightstar Therapeutics : US biotech company Biogen has signed a deal of $800 million to acquire Nightstar Therapeutics, a British clinical-stage gene therapy company, as per the latest pharma acquisition news. Nightstar Therapeutics primarily focuses on the developing adeno-associated virus (AAV) treatments for inherited retinal disorders. Biogen acquisition of Nightstar Therapeutics According […]

Continue reading …
BridgeBio Pharma raises $299m to develop genetic disease drugs

BridgeBio Pharma, a clinical-stage biopharma company focused on the development of drugs for genetic diseases, raised $299.2 million in a new funding round. The California-based biopharma company said that it will utilize the proceeds from the funding round to support its ongoing drug and research and development programs and expand its efforts to accelerate development […]

Continue reading …
FDA accepts to review NDA of Kala’s dry eye drug KPI-121 0.25%

The US Food and Drug Administration (FDA) has accepted to review the New Drug Application (NDA) for KPI-121 0.25%, an investigational dry eye drug, developed by Kala Pharmaceuticals. The US biopharma company is seeking the FDA approval for KPI-121 0.25% to be used for providing temporary relief of signs and symptoms of dry eye disease […]

Continue reading …
Kodiak enrolls patients for retinal disease drug KSI-301’s phase 1 trial

Clinical trial news : Kodiak Sciences has completed enrollment of patients for a phase 1 safety and tolerability study to evaluate its retinal disease drug KSI-301. The California-based biotech company, which is focused on developing therapies for retinal diseases, said that the phase 1 trial for KSI-301 being held in the US is an open […]

Continue reading …